Trovagene (TROV) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Trovagene Announces First Quarter 2017 Company Highlights and Financial Results
May 10, 2017 4:05 PM EDTSAN DIEGO, May 10, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:Â TROV), a precision medicine biotechnology company, today announced company highlights and financial results for the first quarter ended March 31, 2017.Â
"We are excited about the advancement of our business in precision medicine and the development of precision cancer therapeutics for improved cancer care. This includes the licensing and progress in our clinical development plans for PCM-075, our investigational, oral and highly-selective polo-like kinase 1 (PLK1) inhibitor for the treatment of acute myeloid leukemia (AML)," said... More
